| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Chlorogenic acid butyl ester targets the melanogenesis pathway. It inhibits the expression of microphthalmia-associated transcription factor (MITF), a master regulator of melanogenesis. It also inhibits the expression of tyrosinase, TRP-1, and TRP-2, which are key enzymes in melanin biosynthesis. By inhibiting these targets, the compound reduces melanin production.
|
|---|---|
| ln Vitro |
At a dosage of 100 μM, chlorogenic acid butyl ester reduces melanin content by 33-62% and exhibits little or very little damage to cells when it comes to a-MSH-stimulated B16 melanoma cells [1].
Chlorogenic acid butyl ester demonstrates potent in vitro melanogenesis inhibitory activity. At a concentration of 100 µM, it reduces melanin content by 33-62% in α-MSH-stimulated B16 melanoma cells with little or no cytotoxicity. The compound inhibits the expression of MITF, tyrosinase, TRP-1, and TRP-2. It also has antioxidant capacity. |
| ln Vivo |
In vivo activity data for Chlorogenic acid butyl ester are not extensively documented. Its potent melanogenesis inhibitory activity suggests potential in vivo efficacy for skin lightening. Its antioxidant capacity suggests potential in vivo protective effects. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for Chlorogenic acid butyl ester involves measuring its inhibition of tyrosinase activity. Mushroom tyrosinase is commonly used as a model enzyme. The assay typically uses L-DOPA as a substrate, and the formation of dopachrome is monitored spectrophotometrically. Chlorogenic acid butyl ester is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for Chlorogenic acid butyl ester typically use α-MSH-stimulated B16 melanoma cells. Cells are treated with the compound at various concentrations. Melanin content is measured spectrophotometrically. The expression of MITF, tyrosinase, TRP-1, and TRP-2 is analyzed by Western blot or qPCR. Cell viability is assessed to ensure that the observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments for Chlorogenic acid butyl ester are not extensively documented. As a melanogenesis inhibitor, standard in vivo studies would involve animal models of hyperpigmentation. The compound would be administered via topical or oral routes. Melanin content in skin and histopathological analysis would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Chlorogenic acid butyl ester are not extensively documented. As a caffeoylquinic acid ester, it is expected to have moderate bioavailability. Its ester group may be hydrolyzed in vivo. Further pharmacokinetic studies are necessary to fully characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for Chlorogenic acid butyl ester are limited. At 100 µM, it exhibits little or no cytotoxicity in B16 melanoma cells. As a caffeoylquinic acid derivative, it is generally considered to have a favorable safety profile. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
Butyl chloride esters have been reported to be found in Urceola rosea, Isertia haenkeana, and other organisms with available data.
Chlorogenic acid butyl ester is a caffeoylquinic acid derivative and a potent melanogenesis inhibitor. It inhibits the expression of MITF, tyrosinase, TRP-1, and TRP-2. At 100 µM, it reduces melanin content by 33-62% in α-MSH-stimulated B16 melanoma cells with little or no cytotoxicity. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C20H26O9
|
|---|---|
| Molecular Weight |
410.41504
|
| Exact Mass |
410.157
|
| CAS # |
132741-56-1
|
| PubChem CID |
12135130
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
29
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCOC(=O)[C@@]1(C[C@H]([C@H]([C@@H](C1)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O)O
|
| InChi Key |
VNLREARKISTOAD-SNQQTVKYSA-N
|
| InChi Code |
InChI=1S/C20H26O9/c1-2-3-8-28-19(26)20(27)10-15(23)18(25)16(11-20)29-17(24)7-5-12-4-6-13(21)14(22)9-12/h4-7,9,15-16,18,21-23,25,27H,2-3,8,10-11H2,1H3/b7-5+/t15-,16-,18-,20+/m1/s1
|
| Chemical Name |
butyl (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4365 mL | 12.1826 mL | 24.3653 mL | |
| 5 mM | 0.4873 mL | 2.4365 mL | 4.8731 mL | |
| 10 mM | 0.2437 mL | 1.2183 mL | 2.4365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
